IL17A and chordoma: Finally, several other immune features, such as CD45RA, CD57, CD66b, CD68, and IL17, may also be evaluated for their expression profile in chordoma tissues, as well as for eligibility for inclusion in the immune classifier and nomogram, as they have been shown to be indicative of cancer prognosis.22